Sydney, 25 June 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite shareholders to attend information briefing sessions to discuss the company’s recent activities.
Kazia Therapeutics is pleased to make its May 2018 newsletter available to investors via this link.
A prominent Australian oncology researcher says ovarian cancer patients are losing out as badly-needed funds and clinical attention is focused on more prominent – yet not as deadly – women’s diseases.
Kazia Therapeutics (KZA) CEO, Dr James Garner discusses the progress of the company’s two drugs that are in development to treat brain & ovarian cancer.
Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).
CommSec's Tom Piotrowski talks with Kazia Executive Director and CEO Dr James Garner about our company name change to Kazia Therapeutics.
Australian biotechnology company, Novogen has announced that it will change its name to Kazia Therapeutics and that it will consolidate its share register, after the overwhelming majority of shareholders voted in favour of the proposed changes at the company's AGM held in Sydney last week.
CommSec's Tom Piotrowski speaks with Novogen Ltd (NRT) CEO & Executive Director, Dr James Garner about the company’s key milestones over the past 12 months and the clinical trials for its brain cancer treatment drug.
Novogen (ASX: NRT), Chief Executive Officer & Executive Director Dr James Garner , gives an update on Novogen since coming on board in 2016.
CommSec's Tom Piotrowski speaks with Kazia Therapeutics (KZA) CEO & Managing Director, Dr James Garner about the company’s recent name change from Novogen and progress of its ovarian cancer and brain cancer drug trials.
Novogen Sky News Interview
